CEBINA GmbH Press Releases - EIN Presswire - Press Release Distribution Service

Published on August 20, 2026 - 07:36 GMT

New Publication Demonstrates Disease-Modifying Potential of TELOBLOCK in Models of Idiopathic Pulmonary Fibrosis

VIENNA, AUSTRIA, August 20, 2026 /⁨EINPresswire.com⁩/ -- TAG Therapeutics a biotechnology company developing precision medicines for diseases driven by telomere dysfunction, today announces the publication of compelling preclinical data supporting the …

Distribution channels: Science ...

Published on June 30, 2026 - 09:00 GMT

TAG Therapeutics announces publication in Nature Aging providing further evidence for efficacy of the TELOBLOCK approach

VIENNA, AUSTRIA, June 30, 2026 /⁨EINPresswire.com⁩/ -- TAG Therapeutics GmbH, a preclinical-stage biotechnology company dedicated to the development of precision medicine approaches for telomere pathologies and aging-related diseases, today announced the …

Distribution channels: Business & Economy, Companies ...

Published on March 20, 2026 - 06:00 GMT

Eveliqure and Serum Institute of India Announce Strategic Collaboration on the Development of Anti-Diarrhoeal Vaccines

VIENNA, AUSTRIA, March 20, 2026 /⁨EINPresswire.com⁩/ -- Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company focused on Shigella and ETEC vaccine development, and Serum Institute of India (SII), a Cyrus Poonawalla group company and the …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on July 23, 2025 - 07:00 GMT

Eveliqure Announces Dosing of First Participants in a Phase 2b study of the ShigETEC Vaccine in Shigellosis

VIENNA, AUSTRIA, July 23, 2025 /⁨EINPresswire.com⁩/ -- • Phase 2b study to assess immunogenicity and efficacy of the oral ShigETEC vaccine against Shigellosis • Study entails vaccination of participants followed by a Controlled Human Infectious Model ( …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on December 11, 2024 - 10:40 GMT

CEBINA and Danube BioVentures announce the launch of TAG Therapeutics developing a new approach for telomere pathologies

VIENNA, AUSTRIA, December 11, 2024 /⁨EINPresswire.com⁩/ -- Danube Labs, a life science acceleration partnership formed by CEBINA GmbH (Central European Biotech Incubator and Accelerator), Evotec SE and the biotech fund Danube BioVentures, announces the …

Distribution channels: Business & Economy, Companies ...

Published on September 17, 2024 - 12:00 GMT

CEBINA and Charles River Laboratories announce strategic collaboration to accelerate neuroscience research

VIENNA, VIENNA, AUSTRIA, September 17, 2024 /⁨EINPresswire.com⁩/ -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, and Charles River Laboratories International, Inc. (NYSE: CRL), announce today a strategic collaboration within the …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on February 28, 2024 - 10:44 GMT

CEBINA announces the launch of DanubeNeuro, an acceleration program for innovative neuroscience research

VIENNA, AUSTRIA, February 28, 2024 /⁨EINPresswire.com⁩/ -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, announces today the launch of the DanubeNeuro program advancing breakthrough innovative academic research projects in the field of …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on December 18, 2023 - 11:52 GMT

Eveliqure initiates clinical safety, immunogenicity trials of vaccine candidate against Shigellosis, ETEC in Bangladesh

VIENNA, AUSTRIA, December 18, 2023 /⁨EINPresswire.com⁩/ -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, announces the commencement of a Phase 1b clinical trial with ShigETEC, its vaccine candidate against shigellosis and …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on July 4, 2022 - 10:57 GMT

CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

VIENNA, VIENNA, AUSTRIA, July 4, 2022 /⁨EINPresswire.com⁩/ -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent …

Distribution channels: Healthcare & Pharmaceuticals Industry ...